My current research interests encompass elucidation of biomolecular pathways using in vitro iPSC models to define autism spectrum condition (ASC) phenotypes. Defining biomolecular pathways and convergence of such pathways will better guide us to a more robust model for this polygenetic condition. Ultimately this research is geared toward targeting pharmacological intervention that has positive impact on the life of ASC individuals. Further interests of mine are centered on development of iPSC technology, focusing on familial and de novo genetic dosage of deleterious variants that drive autistic phenotypes and/or that interfere with genetic pathways that drive excitatory or inhibitory neuronal networks in the cortex.